T. Rowe Price Investment Management, Inc.

Position in XENE — Xenon Pharmaceuticals Inc.

CIK 1897612 BALTIMORE, MD

Position in XENE

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$55,356,183

+$30,812,169 QoQ

Shares Held

951,955

+73.8% QoQ

Ownership

0.985%

of shares outstanding

% of Portfolio

0.04%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2023

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

T. Rowe Price Investment Management, Inc. holds $11,176,949,825 across 48 Biotechnology names. XENE ranks #29 (0.5% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	5,193,324	$1,718,315,111
2	ASND	Ascendis Pharma A/S	6,162,042	$1,409,443,866
3	CYTK	Cytokinetics Inc	17,523,840	$1,154,996,294
4	APGE	Apogee Therapeutics, Inc.	10,300,984	$867,033,823
5	PCVX	Vaxcyte, Inc.	12,126,017	$704,642,847
6	DYN	Dyne Therapeutics, Inc.	30,785,801	$558,146,572
7	BNTX	BioNTech SE	5,856,073	$520,487,768
8	IONS	Ionis Pharmaceuticals Inc	6,159,027	$462,481,337

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$55,356,183	951,955	+73.8%	Shares	Sole	2026-05-15
2025-12-31	$24,544,014	547,613	-8.6%	Shares	Sole	2026-02-19
2025-09-30	$24,054,386	599,113	+678.6%	Shares	Sole	2025-11-14
2025-06-30	$2,408,315	76,943	-90.3%	Shares	Sole	2025-08-14
2025-03-31	$26,738,880	796,986	-44.6%	Shares	Sole	2025-05-14
2024-12-31	$56,362,975	1,437,831	-4.4%	Shares	Sole	2025-02-14
2024-09-30	$59,204,920	1,503,808	+4.4%	Shares	Sole	2024-11-14
2024-06-30	$56,141,817	1,439,903	+1.0%	Shares	Sole	2024-08-14
2024-03-31	$61,403,893	1,426,339	+60.1%	Shares	Sole	2024-05-15
2023-12-31	$41,046,322	891,149	—	Shares	Sole	2024-02-14
No filing history on record for this holder in this stock.